Kees Lucas is the Non-Executive Board Member of Biotechnol. He spent five years at Biogen Idec where he was part of the senior management team. Kees led the team that wrote the oncology strategy for Biogen, before the merger with Idec Pharmaceuticals. After 5 years as Senior Director Corporate Development he left Biogen-Idec, to become an independent consultant for the biotech industry. Kees has a long and distinguished career in science, pharmaceuticals and business development. He holds a Biochemistry Degree from the University of Delft and a Ph.D. degree in Medicine from Amsterdam University. Kees completed his Management training at IMD, Lausanne, before becoming part-time professor in Neuro-immunology at Amsterdam Free University, where he earned an Emeritus status since through 2010. He worked in immunological research (auto-immunity, vaccines, cancer immunotherapy, transplantation) at the research center of the Dutch Blood Transfusion Service (now ‘Sanquin’). He is a Non-Executive Director of several biotech companies and has a multitude of experience in working with various companies worldwide. His corporate track- includes Chiron, Novartis, Norwood, Bionest, Parteurop, Theraptosis, Faust, Imaxio, Erytech, Envivo, Kempen&Co, Pharmexa, DNAge, CMP Therapeuticals, Inventages, HLA-G technologies, Synvolux and Pfizer. He also works for several VC’s and investment banks. Kees is a citizen of the world and is a respected worldwide key Opinion Leader. He was a member of the Health Council for the For the Dutch government and he represented The Netherlands in UN conferences on de-armament and biological weapons. He was closely involved in worldwide activities around Children’s Vaccines Initiative (CVI, later GAVI). He was also a Key Opinion Leader on Multiple Sclerosis through a large part of his career and was personally responsible for the formation of the Multiple Sclerosis Foundation in the Netherlands for which he received Dutch Royal recognition.

 oncology, pharmaceuticals, biochemistry